Quote | Super Quote
Super Quote   |   Detail Quote   |   Interactive Chart   |   Transaction   |   Related News   |   Related Securities   |   Company Information   |   Dividend Records   |   Short Sell
06160 BEIGENE
RTNominal down77.000 -2.200 (-2.778%)
Others

08/10/2021 15:14

BeiGene (06160) gets approval in Australia

[ET Net News Agency, 8 October 2021] BeiGene, Ltd. (06160) said BRUKINSA (zanubrutinib)
has been approved in Australia for the treatment of adult patients with Waldenstrom's
macroglobulinemia (WM) who have received at least one prior therapy or in first line
treatment for patients unsuitable for chemo-immunotherapy. Following registration of
BRUKINSA with the Australia Therapeutic Goods Administration (TGA), these patients will
have immediate access to BRUKINSA through a BeiGene sponsored post-approval,
pre-reimbursement access program.
In addition, BRUKINSA recently received approval from the Singapore Health Sciences
Authority (HSA) for the treatment of adult patients with mantle cell lymphoma (MCL) who
have received at least one prior therapy. (RC)

Back to Others

Remark: Real time quote last updated: 19/04/2024 18:00
  Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service
A Member of HKET Holdings
Customer Service Hotline:(852) 2880 7004     Customer Service Email:cs@etnet.com.hk
Copyright 2024 ET Net Limited. http://www.etnet.com.hk ET Net Limited, HKEx Information Services Limited, its Holding Companies and/or any Subsidiaries of such holding companies, and Third Party Information Providers endeavour to ensure the availability, completeness, timeliness, accuracy and reliability of the information provided but do not guarantee its availability, completeness, timeliness, accuracy or reliability and accept no liability (whether in tort or contract or otherwise) any loss or damage arising directly or indirectly from any inaccuracies, interruption, incompleteness, delay, omissions, or any decision made or action taken by you or any third party in reliance upon the information provided. The quotes, charts, commentaries and buy/sell ratings on this website should be used as references only with your own discretion. ET Net Limited is not soliciting any subscriber or site visitor to execute any trade. Any trades executed following the commentaries and buy/sell ratings on this website are taken at your own risk for your own account.